Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q2 2021 · 10-Q
Revenue$30.46K$30.46K+388.1% vs Q2 2020 Net Income$3.36M$3.36MN/M vs Q2 2020 EPS Diluted$0.00$0.00— vs Q2 2020 Gross Profit$21,453+739.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Operating Cash Flowderived-$503,536N/M Free Cash Flowderived-$523,750— Margins · derivedGross margin70.4%+29.5 pt vs Q2 2020
Operating margin-1440.3%+1794.8 pt vs Q2 2020
Net margin11038.5%+35181.0 pt vs Q2 2020
ended Jun 30, 2021 · filed Sep 24, 2021 · 86 d after period end